Description

Nuclear medicine is a medical specialty which uses radioactive tracers to diagnose and treat disease. Specially designed cameras allow doctors to track the circulation, uptake and excretion of these radioactive tracers. The global nuclear medicine & radiopharmaceuticals market is poised to grow by US$ 8,003.7 million during 2022-2028, progressing at a CAGR of 10.4% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for nuclear medicine & radiopharmaceuticals. The global nuclear medicine & radiopharmaceuticals market is segmented on the basis of product, application, and region. By product, the global nuclear medicine & radiopharmaceuticals market has been segmented into diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. According to the research, the diagnostic radiopharmaceuticals segment had the largest share in the global nuclear medicine & radiopharmaceuticals market. Based upon application, the global nuclear medicine & radiopharmaceuticals market is categorized into bone metastasis, cardiology, endocrine tumor, hyperthyroidism, lymphoma, oncology, others. Geographically, the global nuclear medicine & radiopharmaceuticals market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global nuclear medicine & radiopharmaceuticals market is highly competitive. The prominent players operating in the global nuclear medicine & radiopharmaceuticals market include Australian Nuclear Science and Technology Organisation (ANSTO), Bracco S.p.A., Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., IBA Molecular (IBAM), IRE – IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Nordion Inc, NTP Radioisotopes SOC Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the nuclear medicine & radiopharmaceuticals market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals
Application: bone metastasis, cardiology, endocrine tumor, hyperthyroidism, lymphoma, oncology, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global nuclear medicine & radiopharmaceuticals market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Nuclear medicine & radiopharmaceuticals market overview
Part 3. Market breakdown by product
– Diagnostic radiopharmaceuticals
– Therapeutic radiopharmaceuticals
Part 4. Market breakdown by application
– Bone metastasis
– Cardiology
– Endocrine tumor
– Hyperthyroidism
– Lymphoma
– Oncology
– Others
Part 5. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 6. Key companies
– Australian Nuclear Science and Technology Organisation (ANSTO)
– Bracco S.p.A.
– Eckert & Ziegler Strahlen- und Medizintechnik AG
– ECZACIBASI-MONROL Nuclear Products Co.
– IBA Molecular (IBAM)
– IRE – IRE ELiT
– Jubilant Life Sciences Ltd.
– Lantheus Holdings, Inc.
– Nordion Inc
– NTP Radioisotopes SOC Ltd.
About StrategyHelix
Disclaimer